Institutional investors hold a majority ownership of BIIB through the 89.44% of the outstanding shares that they control. This interest is also higher than at almost any other company in the Biotechnology industry. Last, during the quarter ended March 2016, these large investors purchased a net $1.3 million shares.
Mutual fund holders
Largest Quarterly Institutional Transactions
Latest Institutional Activity
T. ROWE PRICE ASSOCIATES, INC. Bought 1.8 Million shares of Biogen
FIDELITY MANAGEMENT & RESEARCH C... Bought 545.5 Thousand shares of Biogen
PRIMECAP MANAGEMENT CO. Bought 436.1 Thousand shares of Biogen